scholarly journals BRUTON'S TYROSINE KINASE (BTK) INHIBITOR BGB-3111 DEMONSTRATES HIGH VERY GOOD PARTIAL RESPONSE (VGPR) RATE IN PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA (WM)

2017 ◽  
Vol 35 ◽  
pp. 70-71 ◽  
Author(s):  
J. Trotman ◽  
S. Opat ◽  
P. Marlton ◽  
D. Gottlieb ◽  
D. Simpson ◽  
...  
Keyword(s):  
Partial Response ◽  
Tyrosine Kinase ◽  
Bruton’S Tyrosine Kinase ◽  
Bruton's Tyrosine Kinase ◽  
Waldenström Macroglobulinemia ◽  
Waldenstrom Macroglobulinemia ◽  
Btk Inhibitor ◽  
Good Partial Response

scholarly journals CXCR4 S338X clonality is an important determinant of ibrutinib outcomes in patients with Waldenström macroglobulinemia

2019 ◽  
Vol 3 (19) ◽  
pp. 2800-2803 ◽  
Author(s):  
Joshua N. Gustine ◽  
Lian Xu ◽  
Nicholas Tsakmaklis ◽  
Maria G. Demos ◽  
Amanda Kofides ◽  
...  
Keyword(s):  
Partial Response ◽  
Important Determinant ◽  
Progression Free Survival ◽  
Free Survival ◽  
Waldenström Macroglobulinemia ◽  
Waldenstrom Macroglobulinemia ◽  
Key Points ◽  
Clonality Assessment ◽  
Good Partial Response

Key Points CXCR4 S338X clonality ≥25% is associated with lower very good partial response and shorter progression-free survival to ibrutinib. CXCR4 S338X clonality assessment represents a novel biomarker to predict outcomes to ibrutinib in Waldenström macroglobulinemia patients.

scholarly journals ZYBT1, a potent, irreversible Bruton’s Tyrosine Kinase (BTK) inhibitor that inhibits the C481S BTK with profound efficacy against arthritis and cancer

2020 ◽  
Vol 8 (4) ◽  
Author(s):  
Krishnarup Ghoshdastidar ◽  
Hoshang Patel ◽  
Hitesh Bhayani ◽  
Ankit Patel ◽  
Kinjal Thakkar ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Bruton’S Tyrosine Kinase ◽  
Bruton's Tyrosine Kinase ◽  
Btk Inhibitor
Sign in / Sign up

Export Citation Format

Share Document